<p>勃艮第資產管理有限公司在最近向證券交易委員會提交的文件中表示，在第一季度將其在 Globas Medical, Inc.（紐約證券交易所代碼：GMED - 免費報告）的持倉提高了 7.0%。該機構投資者在此期間額外購買了 183,639 股後，持有該醫療設備公司 2,801,747 股股票。Globas Medical 約佔勃艮第資產管理有限公司持有資產的 2.1%，使其成為第八大持倉。勃艮第資產管理有限公司在最近的報告期末持有 Globas Medical 的股份佔比為 2.04%，價值為 205,088,000 美元。</p>
<p>其他對沖基金也調整了對該公司的持倉。Farther Finance Advisors LLC 在第一季度將其在 Globas Medical 的持倉增加了 145.5%。Farther Finance Advisors LLC 現在持有 405 股該醫療設備公司的股票，價值 30,000 美元，此前在上個季度額外購買了 240 股。Larson Financial Group LLC 在第一季度將其在 Globas Medical 的持倉增加了 1,007.7%。Larson Financial Group LLC 現在持有 432 股該醫療設備公司的股票，價值 32,000 美元，此前在上個季度額外購買了 393 股。Parallel Advisors LLC 在第一季度將其在 Globas Medical 的持倉增加了 62.1%。Parallel Advisors LLC 現在持有 504 股該醫療設備公司的股票，價值 37,000 美元，此前在上個季度額外購買了 193 股。Versant Capital Management Inc 在第一季度將其在 Globas Medical 的持倉增加了 932.1%。Versant Capital Management Inc 現在持有 547 股該醫療設備公司的股票，價值 40,000 美元，此前在上個季度額外購買了 494 股。最後，Whittier Trust Co.在第一季度將其在 Globas Medical 的持倉增加了 46.5%。Whittier Trust Co.現在持有 580 股該醫療設備公司的股票，價值 42,000 美元，此前在上個季度額外購買了 184 股。95.16% 的股票由機構投資者和對沖基金持有。</p>
<p>獲取 <strong>Globas Medical</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>GMED 已成為多份研究分析師報告的主題。Canaccord Genuity Group 在 7 月 22 日的研究報告中將 Globas Medical 的目標價從 97.00 美元下調至 90.00 美元，並對該股票給予 “買入” 評級。巴克萊在 6 月 10 日的研究報告中重申了對 Globas Medical 股票的 “增持” 評級。摩根士丹利在 7 月 15 日的研究報告中將 Globas Medical 的目標價從 75.00 美元下調至 68.00 美元，並對該公司給予 “增持” 評級。Truist Financial 在 5 月 12 日的研究報告中將 Globas Medical 的目標價從 80.00 美元下調至 68.00 美元，並對該公司給予 “持有” 評級。最後，Piper Sandler 在 5 月 9 日的研究報告中將 Globas Medical 的目標價從 100.00 美元下調至 80.00 美元，並對該公司給予 “增持” 評級。五位股票研究分析師對該股票給予 “持有” 評級，九位分析師對該公司給予 “買入” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 87.64 美元。</p>
<p><strong>獲取我們關於 Globas Medical 的最新研究報告</strong></p>
<h2>Globas Medical 股價上漲 1.0%</h2>
<p>GMED 股票在週五開盤價為 60.63 美元。該公司的 50 日移動平均價格為 57.22 美元，200 日移動平均價格為 67.33 美元。該公司的市值為 82.1 億美元，市盈率為 23.32，市盈增長比率為 1.68，貝塔值為 1.20。Globas Medical, Inc.的 1 年最低價為 51.79 美元，1 年最高價為 94.93 美元。</p>
<p>Globas Medical（紐約證券交易所代碼：GMED - 獲取免費報告）在 8 月 7 日發佈了其財報。該醫療設備公司報告本季度每股收益為 0.86 美元，超出市場共識預期的 0.76 美元，超出 0.10 美元。該公司本季度的收入為 7.4534 億美元，而分析師預期為 7.3891 億美元。Globas Medical 的股本回報率為 10.65%，淨利潤率為 13.58%。該公司本季度的收入同比增長 18.4%。在去年同期，該公司每股收益為 0.75 美元。分析師平均預測 Globas Medical, Inc.在本年度的每股收益為 3.44 美元。</p>
<p>Globas Medical 宣佈其董事會於 5 月 15 日啓動了一項股票回購計劃，允許公司回購 5 億美元的流通股。該回購授權允許該醫療設備公司通過公開市場購買最多 6.3% 的股份。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
<h2>Globas Medical 公司簡介</h2>
<p>（免費報告）</p>
<p>Globas Medical, Inc.是一家醫療設備公司，開發和商業化針對美國及國際上肌肉骨骼疾病患者的醫療解決方案。該公司提供脊柱產品，如傳統融合植入物，包括椎弓根螺釘和杆系統、板系統、椎間隔器和用於治療退行性和先天性疾病、畸形、腫瘤和創傷性損傷的椎體切除裝置；運動保留技術的治療選擇，包括動態穩定、全椎間盤置換和椎間分離裝置；治療椎體壓縮骨折的介入解決方案；以及包括同種異體移植物和合成替代品的再生生物產品。</p>
<h2>精選故事</h2>
<ul>
<li>我們更看好的五隻股票比 Globas Medical 更好</li>
<li>何時出售股票以獲利或虧損</li>
<li>3 只能源股以獲得碳捕集熱潮的曝光</li>
<li>10 美元以下的最佳股票</li>
<li>AI 眼鏡會取代智能手機嗎？Meta 正瞄準蘋果</li>
<li>如何計算期權利潤</li>
<li>福特股票上漲的真正原因——它能持續嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何關於此故事的問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Globus Medical 嗎？</h2>
<p>在考慮 Globus Medical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Globus Medical 並不在名單上。</p>
<p>雖然 Globus Medical 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Globus醫療

<p>Burgundy Asset Management Ltd. 在第一季度將其在 Globus Medical, Inc. (NYSE:GMED) 的持股增加了 7.0%，目前擁有 2,801,747 股。該股票佔 Burgundy 持有資產的 2.1%，價值 2.05 億美元。其他對沖基金也顯著增加了他們的持倉。分析師的評級意見不一，普遍共識為 “適度買入”，平均目標價格為 87.64 美元。Globus Medical 報告了強勁的收益，超出預期，並宣佈了一項 5 億美元的股票回購計劃</p>

<p>Burgundy Asset Management Ltd. raised its position in Globus Medical, Inc. (NYSE:GMED - Free Report) by 7.0% in the 1st quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The institutional investor owned 2,801,747 shares of the medical device company's stock after acquiring an additional 183,639 shares during the period. Globus Medical comprises approximately 2.1% of Burgundy Asset Management Ltd.'s holdings, making the stock its 8th largest holding. Burgundy Asset Management Ltd. owned 2.04% of Globus Medical worth $205,088,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>勃艮第資產管理有限公司在最近向證券交易委員會提交的文件中表示，在第一季度將其在 Globas Medical, Inc.（紐約證券交易所代碼：GMED - 免費報告）的持倉提高了 7.0%。該機構投資者在此期間額外購買了 183,639 股後，持有該醫療設備公司 2,801,747 股股票。Globas Medical 約佔勃艮第資產管理有限公司持有資產的 2.1%，使其成為第八大持倉。勃艮第資產管理有限公司在最近的報告期末持有 Globas Medical 的股份佔比為 2.04%，價值為 205,088,000 美元。</p>
</div><p>Other hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC grew its position in Globus Medical by 145.5% during the 1st quarter. Farther Finance Advisors LLC now owns 405 shares of the medical device company's stock worth $30,000 after acquiring an additional 240 shares during the last quarter. Larson Financial Group LLC grew its position in Globus Medical by 1,007.7% during the 1st quarter. Larson Financial Group LLC now owns 432 shares of the medical device company's stock worth $32,000 after acquiring an additional 393 shares during the last quarter. Parallel Advisors LLC grew its position in Globus Medical by 62.1% during the 1st quarter. Parallel Advisors LLC now owns 504 shares of the medical device company's stock worth $37,000 after acquiring an additional 193 shares during the last quarter. Versant Capital Management Inc grew its position in Globus Medical by 932.1% during the 1st quarter. Versant Capital Management Inc now owns 547 shares of the medical device company's stock worth $40,000 after acquiring an additional 494 shares during the last quarter. Finally, Whittier Trust Co. grew its position in Globus Medical by 46.5% during the 1st quarter. Whittier Trust Co. now owns 580 shares of the medical device company's stock worth $42,000 after acquiring an additional 184 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他對沖基金也調整了對該公司的持倉。Farther Finance Advisors LLC 在第一季度將其在 Globas Medical 的持倉增加了 145.5%。Farther Finance Advisors LLC 現在持有 405 股該醫療設備公司的股票，價值 30,000 美元，此前在上個季度額外購買了 240 股。Larson Financial Group LLC 在第一季度將其在 Globas Medical 的持倉增加了 1,007.7%。Larson Financial Group LLC 現在持有 432 股該醫療設備公司的股票，價值 32,000 美元，此前在上個季度額外購買了 393 股。Parallel Advisors LLC 在第一季度將其在 Globas Medical 的持倉增加了 62.1%。Parallel Advisors LLC 現在持有 504 股該醫療設備公司的股票，價值 37,000 美元，此前在上個季度額外購買了 193 股。Versant Capital Management Inc 在第一季度將其在 Globas Medical 的持倉增加了 932.1%。Versant Capital Management Inc 現在持有 547 股該醫療設備公司的股票，價值 40,000 美元，此前在上個季度額外購買了 494 股。最後，Whittier Trust Co.在第一季度將其在 Globas Medical 的持倉增加了 46.5%。Whittier Trust Co.現在持有 580 股該醫療設備公司的股票，價值 42,000 美元，此前在上個季度額外購買了 184 股。95.16% 的股票由機構投資者和對沖基金持有。</p>
</div><p>Get <strong>Globus Medical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Globas Medical</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>GMED has been the topic of a number of research analyst reports. Canaccord Genuity Group decreased their price target on Globus Medical from $97.00 to $90.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, July 22nd. Barclays reissued an &#34;overweight&#34; rating on shares of Globus Medical in a research note on Tuesday, June 10th. Morgan Stanley lowered their target price on Globus Medical from $75.00 to $68.00 and set an &#34;overweight&#34; rating for the company in a research note on Tuesday, July 15th. Truist Financial lowered their target price on Globus Medical from $80.00 to $68.00 and set a &#34;hold&#34; rating for the company in a research note on Monday, May 12th. Finally, Piper Sandler lowered their target price on Globus Medical from $100.00 to $80.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, May 9th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $87.64.</p>
<div class="lb-trans"><p>GMED 已成為多份研究分析師報告的主題。Canaccord Genuity Group 在 7 月 22 日的研究報告中將 Globas Medical 的目標價從 97.00 美元下調至 90.00 美元，並對該股票給予 “買入” 評級。巴克萊在 6 月 10 日的研究報告中重申了對 Globas Medical 股票的 “增持” 評級。摩根士丹利在 7 月 15 日的研究報告中將 Globas Medical 的目標價從 75.00 美元下調至 68.00 美元，並對該公司給予 “增持” 評級。Truist Financial 在 5 月 12 日的研究報告中將 Globas Medical 的目標價從 80.00 美元下調至 68.00 美元，並對該公司給予 “持有” 評級。最後，Piper Sandler 在 5 月 9 日的研究報告中將 Globas Medical 的目標價從 100.00 美元下調至 80.00 美元，並對該公司給予 “增持” 評級。五位股票研究分析師對該股票給予 “持有” 評級，九位分析師對該公司給予 “買入” 評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，平均目標價為 87.64 美元。</p>
</div><p><strong>Get Our Latest Research Report on Globus Medical</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Globas Medical 的最新研究報告</strong></p>
</div><h2>Globus Medical Trading Up 1.0%</h2>
<div class="lb-trans"><h2>Globas Medical 股價上漲 1.0%</h2>
</div><p>GMED stock opened at $60.63 on Friday. The business's 50-day moving average price is $57.22 and its two-hundred day moving average price is $67.33. The firm has a market cap of $8.21 billion, a PE ratio of 23.32, a P/E/G ratio of 1.68 and a beta of 1.20. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $94.93.</p>
<div class="lb-trans"><p>GMED 股票在週五開盤價為 60.63 美元。該公司的 50 日移動平均價格為 57.22 美元，200 日移動平均價格為 67.33 美元。該公司的市值為 82.1 億美元，市盈率為 23.32，市盈增長比率為 1.68，貝塔值為 1.20。Globas Medical, Inc.的 1 年最低價為 51.79 美元，1 年最高價為 94.93 美元。</p>
</div><p>Globus Medical (NYSE:GMED - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical device company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.76 by $0.10. The firm had revenue of $745.34 million for the quarter, compared to analyst estimates of $738.91 million. Globus Medical had a return on equity of 10.65% and a net margin of 13.58%. The company's revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.75 earnings per share. On average, analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current year.</p>
<div class="lb-trans"><p>Globas Medical（紐約證券交易所代碼：GMED - 獲取免費報告）在 8 月 7 日發佈了其財報。該醫療設備公司報告本季度每股收益為 0.86 美元，超出市場共識預期的 0.76 美元，超出 0.10 美元。該公司本季度的收入為 7.4534 億美元，而分析師預期為 7.3891 億美元。Globas Medical 的股本回報率為 10.65%，淨利潤率為 13.58%。該公司本季度的收入同比增長 18.4%。在去年同期，該公司每股收益為 0.75 美元。分析師平均預測 Globas Medical, Inc.在本年度的每股收益為 3.44 美元。</p>
</div><p>Globus Medical announced that its board has initiated a stock buyback plan on Thursday, May 15th that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the medical device company to reacquire up to 6.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.</p>
<div class="lb-trans"><p>Globas Medical 宣佈其董事會於 5 月 15 日啓動了一項股票回購計劃，允許公司回購 5 億美元的流通股。該回購授權允許該醫療設備公司通過公開市場購買最多 6.3% 的股份。股票回購計劃通常表明公司的董事會認為其股票被低估。</p>
</div><h2>Globus Medical Profile</h2>
<div class="lb-trans"><h2>Globas Medical 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.</p>
<div class="lb-trans"><p>Globas Medical, Inc.是一家醫療設備公司，開發和商業化針對美國及國際上肌肉骨骼疾病患者的醫療解決方案。該公司提供脊柱產品，如傳統融合植入物，包括椎弓根螺釘和杆系統、板系統、椎間隔器和用於治療退行性和先天性疾病、畸形、腫瘤和創傷性損傷的椎體切除裝置；運動保留技術的治療選擇，包括動態穩定、全椎間盤置換和椎間分離裝置；治療椎體壓縮骨折的介入解決方案；以及包括同種異體移植物和合成替代品的再生生物產品。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Globus Medical</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>3 Energy Stocks to Gain Exposure to the Carbon Capture Boom</li>
<li>Best Stocks Under $10.00</li>
<li>AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple</li>
<li>How to Calculate Options Profits</li>
<li>The Real Reason Ford Stock Is Rallying—Can It Keep Going?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Globas Medical 更好</li>
<li>何時出售股票以獲利或虧損</li>
<li>3 只能源股以獲得碳捕集熱潮的曝光</li>
<li>10 美元以下的最佳股票</li>
<li>AI 眼鏡會取代智能手機嗎？Meta 正瞄準蘋果</li>
<li>如何計算期權利潤</li>
<li>福特股票上漲的真正原因——它能持續嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdNRUQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=GMED"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何關於此故事的問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Globus Medical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Globus Medical 嗎？</h2>
</div><p>Before you consider Globus Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Globus Medical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Globus Medical 並不在名單上。</p>
</div><p>While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Globus Medical 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Burgundy Asset Management Ltd. 購入了 Globus Medical Inc. (NYSE:GMED) 的股份